Moochhala, Shabbir H.

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Garrelfs, S. F., Frishberg, Y., Hulton, S. A., Koren, M. J., O’Riordan, W. D., Cochat, P., Deschênes, G., Shasha-Lavsky, H., Saland, J. M., van’t Hoff, W. G., et al. (2021) · New England Journal of Medicine

Kidney Stones and Urolithiasis TreatmentsParathyroid Disorders and Treatments

Cited by 531

Genetic variants predisposing to an increased risk of kidney stone disease

Lovegrove, C. E., Goldsworthy, M., Haley, J., Smelser, D., Gorvin, C., Hannan, F. M., Mahajan, A., Suri, M., Sadeghi-Alavijeh, O., Moochhala, S. H., et al. (2025) · Journal of Clinical Investigation

Kidney Stones and Urolithiasis TreatmentsGenetic Associations and Epidemiology

Cited by 18

Genetic variants predisposing to increased risk of kidney stone disease

Lovegrove, C. E., Goldsworthy, M., Haley, J., Diane, S., Gorvin, C., Hannan, F. M., Mahajan, A., Mohnish, S., Sadeghi-Alavijeh, O., Moochhala, S., et al. (2024) · Journal of Clinical Investigation

Kidney Stones and Urolithiasis TreatmentsGenetic Associations and Epidemiology

Cited by 18

How we estimate GFR ? a pitfall of using a serum creatinine-based formula

Refaie, R., Moochhala, S. H., & Kanagasundaram, N. S. (2007) · Clinical Nephrology

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 11